Last10K.com

Actinium Pharmaceuticals, Inc. (ATNM) SEC Filing 10-Q Quarterly report for the period ending Saturday, September 30, 2017

Actinium Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1388320 Ticker: ATNM
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2017
Nov. 03, 2017
Document and Entity Information [Abstract]  
Entity Registrant NameActinium Pharmaceuticals, Inc. 
Entity Central Index Key0001388320 
Trading Symbolatnm 
Amendment Flagfalse 
Current Fiscal Year End Date--12-31 
Document Type10-Q 
Document Period End DateSep. 30, 2017 
Document Fiscal Year Focus2017 
Document Fiscal Period FocusQ3 
Entity Filer CategoryAccelerated Filer 
Entity Common Stock, Shares Outstanding 80,025,639

View differences made from one quarter to another to evaluate Actinium Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Actinium Pharmaceuticals, Inc..

Continue

Assess how Actinium Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Actinium Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets (unaudited)
Consolidated Balance Sheets (unaudited) (parenthetical)
Consolidated Statements Of Cash Flows (unaudited)
Consolidated Statements Of Operations (unaudited)
Commitments And Contingencies
Commitments And Contingencies (details 1)
Commitments And Contingencies (details Textual)
Commitments And Contingencies (details)
Commitments And Contingencies (tables)
Derivatives
Derivatives (details 1)
Derivatives (details Textual)
Derivatives (details)
Derivatives (tables)
Description Of Business And Summary Of Significant Accounting Policies
Description Of Business And Summary Of Significant Accounting Policies (details 1)
Description Of Business And Summary Of Significant Accounting Policies (details Textual)
Description Of Business And Summary Of Significant Accounting Policies (details)
Description Of Business And Summary Of Significant Accounting Policies (policies)
Description Of Business And Summary Of Significant Accounting Policies (tables)
Equity
Equity (details Textual)
Equity (details)
Equity (tables)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (details)
Prepaid Expenses And Other Current Assets (tables)
Property And Equipment
Property And Equipment (details)
Property And Equipment (tables)
Related Party Transactions
Related Party Transactions (details Textual)
Related Party Transactions (details)
Related Party Transactions (tables)

Material Contracts, Statements, Certifications & more

Actinium Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Certification
Exhibit 31.2: Certification
Exhibit 32.1: Certification
Exhibit 32.2: Certification
Ticker: ATNM
CIK: 1388320
Form Type: 10-Q Quarterly Report
Accession Number: 0001213900-17-011347
Submitted to the SEC: Fri Nov 03 2017 4:31:20 PM EST
Accepted by the SEC: Fri Nov 03 2017
Period: Saturday, September 30, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/atnm/0001213900-17-011347.htm